Elagolix treatment for endometriosis-associated pain

Results from a phase 2, randomized, double-blind, placebo-controlled study

Michael Peter Diamond, Bruce Carr, W. Paul Dmowski, William Koltun, Chris O'Brien, Ping Jiang, Joshua Burke, Roland Jimenez, Elizabeth Garner, Kristof Chwalisz

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg once daily for 12 weeks. Placebo patients were rerandomized to elagolix and elagolix patients continued their dosing assignment for 12 additional weeks; the primary efficacy measure was changed from baseline in the monthly mean numerical rating scale for pain at week 12. Monthly mean (standard error of the mean) reductions were greater with elagolix versus placebo (-1.19 ± 0.18,-1.25 ± 0.18, and-0.88 ± 0.18 for elagolix 150 mg, 250 mg, and placebo, respectively); differences were not statistically significant. Monthly mean dysmenorrhea and nonmenstrual pelvic pain scores were reduced with elagolix, with significant differences for dysmenorrhea at weeks 8 and 12 versus placebo (P <.05). Minimal bone mineral density changes were observed with elagolix treatment. In women with endometriosis-associated pain, elagolix demonstrated an acceptable efficacy and safety profile in this Phase 2 study.

Original languageEnglish (US)
Pages (from-to)363-371
Number of pages9
JournalReproductive Sciences
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2014

Fingerprint

Endometriosis
Placebos
Pain
Therapeutics
Dysmenorrhea
elagolix
Safety
Pelvic Pain
Bone Density

Keywords

  • GnRH antagonist
  • elagolix
  • endometriosis

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Elagolix treatment for endometriosis-associated pain : Results from a phase 2, randomized, double-blind, placebo-controlled study. / Diamond, Michael Peter; Carr, Bruce; Dmowski, W. Paul; Koltun, William; O'Brien, Chris; Jiang, Ping; Burke, Joshua; Jimenez, Roland; Garner, Elizabeth; Chwalisz, Kristof.

In: Reproductive Sciences, Vol. 21, No. 3, 01.03.2014, p. 363-371.

Research output: Contribution to journalArticle

Diamond, MP, Carr, B, Dmowski, WP, Koltun, W, O'Brien, C, Jiang, P, Burke, J, Jimenez, R, Garner, E & Chwalisz, K 2014, 'Elagolix treatment for endometriosis-associated pain: Results from a phase 2, randomized, double-blind, placebo-controlled study', Reproductive Sciences, vol. 21, no. 3, pp. 363-371. https://doi.org/10.1177/1933719113497292
Diamond, Michael Peter ; Carr, Bruce ; Dmowski, W. Paul ; Koltun, William ; O'Brien, Chris ; Jiang, Ping ; Burke, Joshua ; Jimenez, Roland ; Garner, Elizabeth ; Chwalisz, Kristof. / Elagolix treatment for endometriosis-associated pain : Results from a phase 2, randomized, double-blind, placebo-controlled study. In: Reproductive Sciences. 2014 ; Vol. 21, No. 3. pp. 363-371.
@article{c8426cac598e406d80b1598db19aa020,
title = "Elagolix treatment for endometriosis-associated pain: Results from a phase 2, randomized, double-blind, placebo-controlled study",
abstract = "This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg once daily for 12 weeks. Placebo patients were rerandomized to elagolix and elagolix patients continued their dosing assignment for 12 additional weeks; the primary efficacy measure was changed from baseline in the monthly mean numerical rating scale for pain at week 12. Monthly mean (standard error of the mean) reductions were greater with elagolix versus placebo (-1.19 ± 0.18,-1.25 ± 0.18, and-0.88 ± 0.18 for elagolix 150 mg, 250 mg, and placebo, respectively); differences were not statistically significant. Monthly mean dysmenorrhea and nonmenstrual pelvic pain scores were reduced with elagolix, with significant differences for dysmenorrhea at weeks 8 and 12 versus placebo (P <.05). Minimal bone mineral density changes were observed with elagolix treatment. In women with endometriosis-associated pain, elagolix demonstrated an acceptable efficacy and safety profile in this Phase 2 study.",
keywords = "GnRH antagonist, elagolix, endometriosis",
author = "Diamond, {Michael Peter} and Bruce Carr and Dmowski, {W. Paul} and William Koltun and Chris O'Brien and Ping Jiang and Joshua Burke and Roland Jimenez and Elizabeth Garner and Kristof Chwalisz",
year = "2014",
month = "3",
day = "1",
doi = "10.1177/1933719113497292",
language = "English (US)",
volume = "21",
pages = "363--371",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Elagolix treatment for endometriosis-associated pain

T2 - Results from a phase 2, randomized, double-blind, placebo-controlled study

AU - Diamond, Michael Peter

AU - Carr, Bruce

AU - Dmowski, W. Paul

AU - Koltun, William

AU - O'Brien, Chris

AU - Jiang, Ping

AU - Burke, Joshua

AU - Jimenez, Roland

AU - Garner, Elizabeth

AU - Chwalisz, Kristof

PY - 2014/3/1

Y1 - 2014/3/1

N2 - This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg once daily for 12 weeks. Placebo patients were rerandomized to elagolix and elagolix patients continued their dosing assignment for 12 additional weeks; the primary efficacy measure was changed from baseline in the monthly mean numerical rating scale for pain at week 12. Monthly mean (standard error of the mean) reductions were greater with elagolix versus placebo (-1.19 ± 0.18,-1.25 ± 0.18, and-0.88 ± 0.18 for elagolix 150 mg, 250 mg, and placebo, respectively); differences were not statistically significant. Monthly mean dysmenorrhea and nonmenstrual pelvic pain scores were reduced with elagolix, with significant differences for dysmenorrhea at weeks 8 and 12 versus placebo (P <.05). Minimal bone mineral density changes were observed with elagolix treatment. In women with endometriosis-associated pain, elagolix demonstrated an acceptable efficacy and safety profile in this Phase 2 study.

AB - This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg once daily for 12 weeks. Placebo patients were rerandomized to elagolix and elagolix patients continued their dosing assignment for 12 additional weeks; the primary efficacy measure was changed from baseline in the monthly mean numerical rating scale for pain at week 12. Monthly mean (standard error of the mean) reductions were greater with elagolix versus placebo (-1.19 ± 0.18,-1.25 ± 0.18, and-0.88 ± 0.18 for elagolix 150 mg, 250 mg, and placebo, respectively); differences were not statistically significant. Monthly mean dysmenorrhea and nonmenstrual pelvic pain scores were reduced with elagolix, with significant differences for dysmenorrhea at weeks 8 and 12 versus placebo (P <.05). Minimal bone mineral density changes were observed with elagolix treatment. In women with endometriosis-associated pain, elagolix demonstrated an acceptable efficacy and safety profile in this Phase 2 study.

KW - GnRH antagonist

KW - elagolix

KW - endometriosis

UR - http://www.scopus.com/inward/record.url?scp=84896879235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896879235&partnerID=8YFLogxK

U2 - 10.1177/1933719113497292

DO - 10.1177/1933719113497292

M3 - Article

VL - 21

SP - 363

EP - 371

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 3

ER -